Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 5/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310319 | 0.84 | SIGMAR1 (0.49) | TRPV6ALDH1A1DRD4 | |
| SCHEMBL1189566 | 0.84 | SIGMAR1 (0.49) | TRPV6ALDH1A1DRD4 | |
| SCHEMBL29615692 | 0.81 | TRPV6 (0.62) | TRPV6CHRNB2CHRNA4OPRM1OPRD1 | |
| SCHEMBL29615698 | 0.81 | TRPV6 (0.62) | TRPV6CHRNB2CHRNA4OPRM1OPRD1 | |
| SCHEMBL20528276 | 0.79 | PIK3CA (0.39) | TRPV6 | |
| SCHEMBL18201926 | 0.79 | PIK3CA (0.39) | TRPV6 | |
| SCHEMBL31329931 | 0.78 | TRPV6 (0.80) | TRPV6CHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL4970159 | 0.76 | CHRNB2 (0.72) | TRPV6CHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL21553313 | 0.76 | CNR2 (0.41) | TRPV6 | |
| SCHEMBL16026435 | 0.74 | CHRNB2 (0.85) | TRPV6CHRNB2CHRNA4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | TRPV6 3973/4885CHRNB2 3875/4885CHRNA4 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.